Madrigal Pharmaceuticals’ (MDGL) Buy Rating Reaffirmed at Truist Financial

Madrigal Pharmaceuticals (NASDAQ:MDGL)‘s stock had its “buy” rating restated by investment analysts at Truist Financial in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $743.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $709.00. Truist Financial‘s price objective suggests a potential upside of 94.01% from the stock’s previous close.

MDGL has been the subject of a number of other reports. HC Wainwright reaffirmed a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, October 15th. Citigroup increased their price objective on shares of Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the stock a “buy” rating in a research report on Tuesday. Barclays decreased their price objective on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. Finally, Wolfe Research raised shares of Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price objective for the company in a research note on Tuesday, August 4th. Fourteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $703.80.

Madrigal Pharmaceuticals Trading Down 3.4%

NASDAQ:MDGL traded down $13.35 during midday trading on Wednesday, hitting $382.98. 1,084,207 shares of the company traded hands, compared to its average volume of 340,282. The firm’s fifty day moving average is $494.64 and its 200-day moving average is $498.92. Madrigal Pharmaceuticals has a 12-month low of $353.54 and a 12-month high of $615.00. The firm has a market capitalization of $8.85 billion, a P/E ratio of -29.34 and a beta of -0.98. The company has a current ratio of 3.20, a quick ratio of 2.94 and a debt-to-equity ratio of 0.65.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, topping the consensus estimate of ($1.09) by $2.92. The company had revenue of $431.27 million during the quarter, compared to analyst estimates of $404.17 million. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. During the same period in the previous year, the firm earned ($5.08) earnings per share. On average, sell-side analysts predict that Madrigal Pharmaceuticals will post -7.03 EPS for the current year.

Insider Transactions at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, CEO William Sibold sold 6,362 shares of Madrigal Pharmaceuticals stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $535.59, for a total transaction of $3,407,423.58. Following the completion of the sale, the chief executive officer directly owned 202,967 shares of the company’s stock, valued at $108,707,095.53. The trade was a 3.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Shannon T. Kelley sold 664 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $514.97, for a total value of $341,940.08. Following the completion of the sale, the general counsel owned 11,474 shares of the company’s stock, valued at $5,908,765.78. This represents a 5.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 12,247 shares of company stock worth $6,581,182 over the last 90 days. Insiders own 17.60% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in MDGL. Brighton Jones LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the 3rd quarter valued at $988,000. Ethic Inc. boosted its position in shares of Madrigal Pharmaceuticals by 20.6% in the 3rd quarter. Ethic Inc. now owns 598 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 102 shares in the last quarter. Parallel Advisors LLC grew its stake in Madrigal Pharmaceuticals by 32.2% during the 3rd quarter. Parallel Advisors LLC now owns 349 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 85 shares during the last quarter. Allegiance Financial Group Advisory Services LLC purchased a new position in Madrigal Pharmaceuticals during the 3rd quarter worth $219,000. Finally, Calamos Advisors LLC grew its stake in Madrigal Pharmaceuticals by 83.3% during the 3rd quarter. Calamos Advisors LLC now owns 3,009 shares of the biopharmaceutical company’s stock worth $1,516,000 after buying an additional 1,367 shares during the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Third-quarter EPS was $1.83, well ahead of analysts’ expected loss of $1.09, while revenue of $431.27 million topped estimates of $404.17 million. Rezdiffra sales reportedly surpassed $1 billion, with sales up 50%. Madrigal third-quarter 2026 results
• Positive Sentiment: Citigroup raised its price target to $760 and maintained a Buy rating, signaling substantial potential upside in the analyst’s view. Citigroup price-target update
• Neutral Sentiment: Madrigal expects a MAESTRO-NASH OUTCOMES readout in late 2027 and is planning a study of more than 2,000 patients. These programs may provide future catalysts, but the timing is relatively distant. Clinical-trial update
• Negative Sentiment: Despite the earnings beat, coverage pointed to near-term profitability concerns as a factor behind the stock’s weakness. Separately, Kaplan Fox announced an investigation into potential securities-law violations. The announcement is an investigation notice, not a finding of wrongdoing. Report on profitability concerns Kaplan Fox investigation announcement

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.